Is there any information on the efficacy of the EGFR (epidermal growth factor receptor)/HER2 (human epidermal growth factor receptor 2) peptide vaccine in dogs with mammary spindle‑cell carcinoma?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 21, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

EGFR/HER2 Vaccine Efficacy in Canine Mammary Spindle Cell Carcinoma

Direct Answer

There is limited but promising evidence that EGFR/HER2 peptide vaccines can induce functional anti-tumor immunity in dogs with EGFR-expressing mammary tumors, though specific data on spindle cell carcinoma histology is not available. 1

Evidence for EGFR/HER2 Vaccine in Canine Mammary Tumors

Demonstrated Vaccine Efficacy

  • A phase I/II study demonstrated that dogs with EGFR-expressing tumors immunized with a short peptide of the EGFR extracellular domain (with HER2 sequence homology) developed high-titer antibodies with biological activity similar to cetuximab and trastuzumab. 1

  • The vaccine-induced antibodies bound both canine and human EGFR on tumor cell lines and tumor tissue, inhibited EGFR intracellular signaling, and inhibited tumor growth in vitro. 1

  • Objective responses were documented with tumor reduction at metastatic sites in vaccinated host animals. 1

  • CD8 T cell infiltration and IgG deposition were evident in tumors from immunized dogs, indicating both cellular and humoral immune responses. 1

Biological Rationale

  • The canine HER-2 homologue (DER-2) shares 92% amino acid identity with human HER-2 and has similar biological implications as in human breast cancer. 2

  • HER-2 overexpression occurs in 35.3% of malignant canine mammary tumors, making it a relevant therapeutic target. 3

  • DNA electroporation and Adenovirus serotype 6-based vaccines against canine TERT and HER-2/neu induced long-lasting adaptive immune responses in healthy dogs without autoimmunity or side effects. 4

Critical Limitations for Spindle Cell Carcinoma

Lack of Histology-Specific Data

  • None of the available studies specifically report outcomes for mammary spindle cell carcinoma as a distinct histological subtype. The phase I/II vaccine study included dogs with "EGFR expressing tumors" but did not stratify results by specific histological classification. 1

  • Spindle cell carcinomas represent a morphologically distinct subtype that may have different EGFR/HER2 expression patterns compared to other mammary carcinoma subtypes.

Expression Pattern Considerations

  • Before considering vaccine therapy, immunohistochemical confirmation of EGFR and/or HER-2 overexpression in the specific spindle cell carcinoma is essential, as expression varies significantly among canine mammary tumor subtypes. 3

  • HER-2 overexpression was identified in only 35.3% of malignant canine mammary tumors overall, meaning a substantial proportion would not be appropriate vaccine candidates. 3

Practical Clinical Approach

Pre-Vaccination Requirements

  • Perform immunohistochemistry for EGFR and HER-2 expression on the spindle cell carcinoma tissue before considering vaccine therapy. 1, 3

  • Confirm adequate EGFR/HER-2 expression (ideally 2+ or 3+ by IHC scoring) to justify vaccine-based targeting.

Expected Outcomes

  • If EGFR/HER-2 expression is confirmed, the vaccine approach may induce trastuzumab-like and cetuximab-like antibodies that can bind tumor cells and inhibit growth signaling. 1

  • The vaccine may be most relevant when combined with other immune-modifying therapies such as checkpoint inhibitors, as suggested by the translational study data. 1

Comparison to Alternative Approaches

  • Autologous DC-based fusion vaccines for canine mammary carcinoma showed vaccinated patients survived 3.3-times longer (median 611 days) compared to controls (median 184 days), though this approach differs mechanistically from peptide vaccines. 5

  • However, inflammatory mammary carcinoma showed no vaccine benefit (median survival 42 days), indicating that highly aggressive subtypes may not respond to vaccine-based immunotherapy. 5

Common Pitfalls

  • Do not assume vaccine efficacy applies uniformly across all mammary carcinoma histological subtypes—spindle cell carcinomas may behave differently than the mixed populations studied in published trials. 1

  • Avoid vaccine therapy without confirming target antigen expression, as approximately 65% of malignant canine mammary tumors do not overexpress HER-2. 3

  • Recognize that vaccine-induced immunity requires time to develop and may not be appropriate for rapidly progressive or life-threatening disease where immediate cytoreduction is needed.

References

Related Questions

What are the origin roots, motor and sensory functions, and most common injuries of the musculocutaneous nerve?
What is an appropriate sliding‑scale dosing protocol for regular (short‑acting) insulin in adult inpatients?
What is the recommended duration of anticoagulation for a deep‑vein thrombosis provoked by prolonged immobilization in a cast?
How should I manage impetigo and nasal congestion in a 1‑month‑old infant with limited non‑bullous lesions and no severe penicillin allergy?
What is the first‑line rescue inhaler for acute bronchospasm in asthma and chronic obstructive pulmonary disease, and what is the recommended dosing?
What are the recommended adult and pediatric dosing regimens, side effects, contraindications, and safety considerations for ondansetron in preventing chemotherapy, radiation, postoperative, and pregnancy‑related nausea?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question